sponsored byAAAS Golden Fund

Username:

Password:

Register

Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books

Meetings

Multimedia

Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation

Calendar

Submit a Calendar Item

Subscribe/Sponsor

Links & Resources

Portals

RSS Feeds

Accessibility Option On

Options

Portal Home

Glossary

Background Articles

Research Papers

Meetings

Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 201-225 out of 1342.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>

Public Release: 14-Nov-2016
American Journal of Ophthalmology
Researchers find a better way to save eyesight in third-world countries
A new study in the American Journal of Ophthalmology reports that low-cost widely available eye drops are just as effective as antibiotics in treating bacterial keratitis, a leading cause of blindness.

Contact: Laura Mecoy
LMecoy@LABioMed.org
310-546-5860
LA BioMed

Public Release: 14-Nov-2016
2016 Annual Meeting of the American Society of Tropical Medicine and Hygiene
New evidence finds mosquitoes could infect humans with Zika and chikungunya viruses at the same time
Mosquitoes are capable of carrying Zika and chikungunya viruses simultaneously and can secrete enough in their saliva to potentially infect humans with both viruses in a single bite, according to new research presented today at the 2016 Annual Meeting of the American Society of Tropical Medicine and Hygiene.

Contact: Preeti Singh
psingh@burness.com
301-280-5722
Burness

Public Release: 14-Nov-2016
2016 Annual Meeting of the American Society of Tropical Medicine and Hygiene
New study ties West Nile virus to risk of shorter life span
West Nile virus may be much more deadly than previously believed, with deaths attributable to the mosquito-borne disease occurring not just in the immediate aftermath of the infection but also years later, long after patients seem to have recovered from the initial illness, according to a new study presented today at the 2016 Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

Contact: Preeti Singh
psingh@burness.com
301-280-5722
Burness

Public Release: 11-Nov-2016
GUMC selects global health champion Roger I. Glass as recipient of highest award
Georgetown University Medical Center will honor Roger I. Glass, MD, PhD, with the 2016 Cura Personalis Award at its Ninth Annual GUMC Convocation on Thursday, Nov. 17. Glass also will be the Convocation keynote speaker.

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 11-Nov-2016
Current Cancer Therapy Reviews
Antibody drug conjugates have shown clinical efficacy with acceptable toxicity
Antibody drug conjugates have shown a clearly documented efficacy and acceptable toxicity and can be easily implemented in oncology departments where chemotherapy administration is a routine practice. A similar efficacy with acceptable toxicity has been documented with antibody radionuclide conjugates which need to be injected with the help of a nuclear medicine department which can be a limitation for referral from an oncologist.

Contact: Faizan ul Haq
faizan@benthamscience.org
Bentham Science Publishers

Public Release: 11-Nov-2016
Current Diabetes Reviews
The effect of exercise on vascular function and stiffness in type 2 diabetes
A new study from the University of Sydney has found that regular aerobic exercise can improve artery health in people with type 2 diabetes. The findings from this study have been published in Current Diabetes Reviews, and shed new light on exercise as a therapy in this population.

Contact: Faizan ul Haq
faizan@benthamscience.org
Bentham Science Publishers

Public Release: 10-Nov-2016
International consortium receives $36.9 million grant to fight typhoid
Typhoid fever remains a serious global problem: it kills almost a quarter of a million people annually. To help promote typhoid vaccines, the Bill & Melinda Gates Foundation has given a $36.9 million grant to the University of Maryland School of Medicine Center for Vaccine Development. The project is a partnership with the Oxford Vaccine Group and PATH.

Contact: David Kohn
dkohn@som.umaryland.edu
410-706-7590
University of Maryland School of Medicine

Public Release: 10-Nov-2016
Science
Childhood infections provide lifelong protection against flu viruses from animals
People gain lifelong, partial protection against novel influenza viruses that are genetically similar to the influenza viruses they first encountered during childhood, life scientists from UCLA and the University of Arizona report in the journal Science.

Contact: Stuart Wolpert
swolpert@support.ucla.edu
310-206-0511
University of California - Los Angeles

Public Release: 8-Nov-2016
PLOS Medicine
Giving women HIV self-tests promotes male partner testing
Providing pregnant and postpartum women in sub-Saharan Africa with multiple HIV self-tests can make it more likely their male partners will be tested for HIV compared to a standard approach of distributing invitation cards for clinic-based testing, according to a randomized trial published in PLOS Medicine by Harsha Thirumurthy of the University of North Carolina at Chapel Hill, USA, and colleagues.

Contact: Harsha Thirumurthy
harsha@unc.edu
PLOS

Public Release: 7-Nov-2016
Lancet
Funding a set of essential medicines for low- and middle-income countries
As the world moves toward universal health coverage, the question arises: how can governments ensure equitable access to essential medicines in low- and middle-income countries? A section of The Lancet Commission on Essential Medicines Policies report co-written by Corrina Moucheraud, assistant professor of health policy and management at the UCLA Fielding School of Public Health, provides the first comprehensive model estimating the cost to provide essential medicines for all people in these countries.

Contact: Enrique Rivero
erivero@mednet.ucla.edu
310-267-7120
University of California - Los Angeles Health Sciences

Public Release: 7-Nov-2016
UNC scientists named to European Union-funded global Zika research consortium
Two researchers at the UNC School of Medicine have been named to a global consortium for Zika research and vaccine development. Aravinda de Silva, PhD, professor of microbiology and immunology, and Stefan Metz, PhD, a post-doc in de Silva's lab, make up one of only two US teams to be named to the European Union-funded worldwide initiative. Sponsored by the European Union's Horizon 2020 Programme, the consortium is investing $49 million in Zika research across the globe.

Contact: Caroline Curran
caroline.curran@unchealth.unc.edu
984-974-1146
University of North Carolina Health Care

Public Release: 7-Nov-2016
Nature
Early study finds antibody that 'neutralizes' Zika virus
Researchers studied Zika survivors and made human monoclonal antibodies from their B cells that kill the virus. In mouse models of infection including pregnant mice, some of the antibodies protect against infection and disease including the fetuses.
National Institutes of Health

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center

Public Release: 7-Nov-2016
Nature
Antibody protects against fetal disease in mouse model of Zika infection
Administering a human antibody that neutralizes Zika virus to pregnant mice before or after Zika virus infection reduced levels of the virus in placental and fetal tissues and decreased fetal disease, new findings show. The work may aid development of vaccines and therapies for Zika virus infection, which can cause severe birth defects when it occurs during pregnancy.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Hillary Hoffman
hillary.hoffman@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 7-Nov-2016
Proceedings of the National Academy of Sciences
Mosquito-borne illness spreads in and around homes, disproportionately hits women
Outbreaks of the mosquito-borne disease chikungunya appear to be driven by infections centered in and around the home, with women significantly more likely to become ill, suggests new research from the Johns Hopkins Bloomberg School of Public Health, the Institut Pasteur in Paris and the International Centre for Diarrhoeal Disease Research, Bangladesh.
US Centers for Disease Control and Prevention, NIH/National Institute of Allergy and Infectious Diseases

Contact: Stephanie Desmon
sdesmon1@jhu.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health

Public Release: 4-Nov-2016
An integrated approach to HIV prevention
The Medical University of South Carolina has received a $3.1 million grant from the National Institutes of Health to study an integrated approach of screening and treatment for HIV, diabetes, and hypertension in Tanzania. In an earlier small study, this approach resulted in a 97 percent increase in HIV testing over twelve months. This new trial is a collaborative effort between MUSC, Clemson University, and Muhimbili University of Health and Allied Sciences in Tanzania.
National Institutes of Health

Contact: Heather Woolwine
woolwinh@musc.edu
843-792-7669
Medical University of South Carolina

Public Release: 3-Nov-2016
The Open Dentistry Journal
Dental occlusion and ophthalmology: A literature review
Dental Occlusion and Ophthalmology: A Literature Review is a summary of many years of research and dental clinic of Orofacial Pain Department directed by Professor Monaco of University of L'Aquila on a complex subject: connections between temporomandibular joints and vision. The authors' primary goal is to give clinical advice starting from the study of anatomical and functional connections between dental occlusion and vision.

Contact: Faizan ul Haq
faizan@benthamscience.org
Bentham Science Publishers

Public Release: 3-Nov-2016
Lancet Infectious Diseases
Two genetic markers that predict malaria treatment failure found
A malaria treatment that combines fast-acting dihydroartemisinin with long-lasting piperaquine is quickly losing power in Cambodia due to the rapid spread of drug-resistant parasites. The presence of piperaquine-resistant malaria parasites in several Cambodian provinces was confirmed earlier this year. Now, by comparing the complete genomes of 297 parasites isolated from Cambodian malaria patients to a reference malaria parasite genome, researchers identified two genetic markers that are strongly associated with the parasites' ability to resist piperaquine.
NIH/National Institute of Allergy and Infectious Diseases

Contact: NIAID Office of Communications
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 3-Nov-2016
IDRI receives $15 million commitment from Eli Lilly for TB drug discovery
IDRI's drug discovery efforts continue to grow with a recently awarded $7.5 million in additional funding, plus an additional $7.5 million of in-kind services, for a total commitment of $15 million over the next five years from Eli Lilly and Company.
Eli Lilly and Company

Contact: Lee Schoentrup
lee.schoentrup@idri.org
425-354-8132
Infectious Disease Research Institute

Public Release: 3-Nov-2016
Cell
New TSRI study suggests Ebola can adapt to better target human cells
A new study co-led by scientists at The Scripps Research Institute (TSRI) suggests that Ebola virus gained a genetic mutation during the 2013-16 epidemic that appears to have helped it better target human cells.
National Institutes of Health, NIH/National Institute National Institute on Drug Abuse, NIH/National Institute of Allergy and Infectious Diseases, NIH/National Human Genome Research Institute, NIH/National Center for Advancing Translational Sciences

Contact: Madeline McCurry-Schmidt
madms@scripps.edu
858-784-9254
Scripps Research Institute

Public Release: 3-Nov-2016
Lancet Infectious Diseases
Genetic marker found for resistance to malaria treatment in Cambodia
Scientists at the Wellcome Trust Sanger Institute and their collaborators have discovered genetic markers in malaria parasites linked with resistance to the anti-malarial drug piperaquine. Reported in Lancet Infectious Diseases, this research will allow health officials to monitor the spread of resistance, and help doctors and public health officers decide where the treatment is most likely to be effective.
NIH/National Institute of Allergy and Infectious Diseases, National Institutes of Health, Wellcome Trust, Bill & Melinda Gates Foundation, Medical Research Council, and UK Department for International Development

Contact: Samantha Wynne
press.office@sanger.ac.uk
122-349-2368
Wellcome Trust Sanger Institute

Public Release: 3-Nov-2016
More than 3 million children under 5 years old will die from infectious diseases next year
A new report outlines the alarming burden of pediatric infectious diseases across the world.
Global Hygiene Council

Contact: Catherine Major
catherine@spinkhealth.com
01-444-811-099
Global Hygiene Council

Public Release: 2-Nov-2016
Lancet Oncology
Safety concerns linger for generic oncology drugs in developing countries
Although generic oncology drugs can reduce patient costs and improve treatment access, the safety of these drugs in developing countries is uncertain, according to an international research team led by Dr. Charles Bennett, Josie M. Fletcher professor and chairman of the S.C. SmartState Center in Medication Safety and Efficacy at the College of Pharmacy at the University of South Carolina.
NIH/National Cancer Institute, SmartState/State of South Carolina

Contact: Laura Kammerer
laurakam@mailbox.sc.edu
803-777-4731
University of South Carolina

Public Release: 2-Nov-2016
World Journal of Surgery
WHO Trauma Care Checklist improves care for injured patients
Injury is responsible for more than 10 percent of the global burden of disease, killing more people each year than HIV, malaria and tuberculosis combined. More than 90 percent of these deaths occur in low- and middle-income countries. Injury is also the leading cause of death in adolescents globally.

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer

Public Release: 2-Nov-2016
BMC Medicine
Prevalence of drug-resistant tuberculosis in West Africa higher than previously thought
Multidrug-resistant tuberculosis could become a serious public health threat in West Africa unless effective surveillance and control measures are implemented, according to a study published in the open access journal BMC Medicine. Researchers from the West-African Network of Excellence for TB, AIDS and Malaria found the prevalence of multidrug-resistant tuberculosis to be unexpectedly high in eight West-African countries.
European Developing Countries Clinical Trial Partnership

Contact: Anne Korn
anne.korn@biomedcentral.com
44-020-319-22744
BioMed Central

Public Release: 1-Nov-2016
World Cancer Congress
Merck KGaA, Darmstadt, Germany, and American Cancer Society address cancer in women
Merck KGaA, Darmstadt, Germany, a leading science and technology company, and the American Cancer Society today released a report that shows all four of the top causes of cancer deaths in women worldwide are mostly preventable or can often be detected early, when treatment is more successful. The report, titled 'The Global Burden of Cancer in Women,' is the first tangible output from an innovative partnership between Merck KGaA, Darmstadt, Germany, and the ACS.
Merck KGaA, American Cancer Society

Contact: Gangolf Schrimpf
49-615-172-9591
Merck KGaA, Darmstadt, Germany

Showing releases 201-225 out of 1342.

<< < 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 > >>